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Effect of a novel adsorbent on cytokine responsiveness to ure- biocompatible dialyzer membranes, and bacterial infec-
mic plasma. tions induce the release of proinflammatory cytokines,
Background. Middle molecules such as 2-microglobulin which generate an acute phase reaction. This results in a(2M) and advanced glycation end products (AGE)–modified
chronic microinflammatory state, which increases cardio-proteins contribute to inflammation in uremia. The BetaSorb
vascular morbidity [1]. Furthermore, retention of middlecolumn is a new adsorptive device, which contains copolymeric
beads, suitable for removal of 2M and other middle molecules. molecules such as 2-microglobulin (2M) may also inde-
We assessed the effect of this column on the bioreactivity of pendently contribute to this inflammatory state by pro-
uremic plasma, as measured by cytokine responsiveness. moting cytokine generation. Interestingly, human 2MMethods. Uremic plasma was perfused in vitro through the
per se has not been reported to directly affect cytokinecolumn (10 mL/min) and samples were collected after 10 to 30
generation whereas the modification of 2M by advancedpasses. Endotoxin-stimulated tumor necrosis factor- (TNF-)
and interleukin-10 (IL-10) production by THP-1–derived glycation end products (AGE-2M) can result in many
monocytes was measured following brief exposure to uremic biological activities including production of proinflam-
plasma. 2M levels were measured. The contribution of AGE- matory cytokines such as interleukin-1 (IL-1) and tu-modified proteins to the bioreactivity of uremic plasma was
mor necrosis factor- (TNF-) [2], matrix expansion,explored.
Results. TNF- and IL-10 production markedly decreased vascular damage, and accelerated atherosclerosis [3].
after 30 passes (629  78 vs. 144  62 pg/mL; 207  25 vs. Therefore, removal of uremic toxins, including native
117  23 pg/mL; P  0.04). The column removed 2M effi- and AGE-modified middle molecules, may prevent or
ciently with a marked decline in plasma levels by 99% after
at least reduce the uremia-induced inflammatory re-30 passes. Neutralization of AGE receptor (RAGE) resulted
sponses. Modalities for removal of middle moleculesin a further reduction in the bioreactivity of uremic plasma. This
was observed with nonperfused, as well as perfused, uremic from the blood include diffusive, convective, and adsorp-
plasma, suggesting that AGE-modified proteins were biologi- tive techniques such as hemoperfusion. The latter ap-
cally active and still present after perfusion. proach employs matrices that bind the hydrophobic moi-Conclusion. The sorbent beads removed uremic solute(s)
eties of middle molecules [4]. Recent advances in thesethat prime monocytes to enhanced cytokine production. Re-
technological approaches have led to the developmentmoval of 2M was efficient, and of native and AGE-modified
middle molecules likely. of a new adsorption column, which contains hyper-cross-
linked styrene divinylbenzene copolymer beads (Beta-
Sorb, RenalTech International, New York, NY, USA)
[5–7]. The sorbent beads contained in this column haveHemodialysis patients are constantly exposed to a mi-
croinflammatory environment. Indeed, exposure to bac- a pore size distribution of 2 to 20 A˚, which is suitable
terial contaminants from dialysis water systems, poorly for removing molecules in the weight range of 0.3 to 15.0
kD, and restricting adsorption of larger molecules such as
serum albumin [5, 6]. A list of putative plausible uremic
Key words: hemoperfusion, adsorbent, beads, middle molecules, ure- toxins removed by this sorbent have been reviewed pre-
mic toxins, 2-microglobulin, amyloidosis, advanced glycation end viously [6]. Ex vivo (abstract; Bosch et al, J Am Socproducts, inflammation, cytokines, tumor necrosis factor-, interleu-
kin-10. Nephrol 11: 257A, 2000), animal (abstracts; Brady et al,
J Am Soc Nephrol 11: 560A, 2000; Cowgill et al, ASAIOReceived for publication May 1, 2002
J: 47:61, 2001), and preliminary clinical studies [7] haveand in revised form September 3, 2002, and October 3, 2002
Accepted for publication October 29, 2002 demonstrated 95% removal of 2M by this column, with
high degree of biocompatibility [7]. By contrast, little 2003 by the International Society of Nephrology
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is known of the effect of this column on inflammatory THP-1 cell culture
responses. For these studies, we used the human promonocytic
The objectives of this study were to assess whether THP-1 cell line, which was originally characterized by
the removal of middle molecules by the sorbent beads Tsuchiya et al [8]. This cell line has distinct human mono-
contained in the BetaSorb column affects the bioreac- cytic markers, and during culture, THP-1 cells maintain
tivity of uremic plasma. We hypothesized that uremic these monocytic characteristics [8]. Furthermore, THP-1
plasma primes monocytes to enhance cytokine respon- cells express CD14 and Toll-like receptors [9], two im-
siveness, and that the sorbent beads reduce this “priming portant LPS ligands.
effect.” TNF- and IL-10 production by endotoxin-stim- In brief, THP-1 cells were grown in suspension culture
ulated THP-1–derived monocytes were used as indica- at the concentration of 0.25  106 cells/mL in RPMI-
1640 medium (Sigma Aldrich Chemical) containing 10%tors of cytokine responsiveness following brief exposure
heat-inactivated fetal bovine serum (FBS), 100 U/mLto uremic plasma. Plasma 2M was measured as a surro-
penicillin, 100 g/mL streptomycin, and 0.25 g/mL fun-gate marker of middle molecules. Finally, in separate
gizone. Cells were maintained in a humidified atmo-experiments, the contribution of AGE-modified proteins
sphere with 5% CO2 at 37oC. Differentiation to mono-to the bioreactivity of uremic plasma was explored.
cytes (0.35  106 cells/mL) was induced by incubating
cells with transretinoic acid (1 mol/L), 1,25 dihydroxy
METHODS cholecalciferol (107 M), and interferon- (105 g/L) for
3 days [10].Reagents
The human promonocytic THP-1 cell line was obtained TNF- and IL-10 production by THP-1–derived monocytes
from the American Tissue Culture Collection ATCC
To examine the effect of the sorbent column on cyto-(Rockville, MD, USA). All culture reagents were pur-
kine responsiveness, differentiated THP-1 cells (0.7106chased from Gibco Life Technologies (Rockville, MD,
cells/mL) were incubated for 2 hours in a humidifiedUSA). Trans-retinoic acid, 1,25 dihydroxy cholecalcif-
atmosphere with 5% CO2 and at 37	C with uremicerol, interferon-, purified Escherichia coli lipopolysac-
plasma before (pass 0) and after 30 passes (pass 30) overcharide (LPS) (serotype 055:B5) and glucose were ob-
the column. The plasma was then removed, and cellstained from Sigma Aldrich Chemical (St. Louis, MO,
were washed with phosphate-buffered saline (PBS) andUSA). 2M, TNF- and IL-10 ELISA kits were pur- stimulated with 10 ng/mL of LPS for 16 hours. Cell super-chased from R&D Systems (Minneapolis, MN, USA).
natants were aspirated, and TNF- and IL-10 were mea-Receptor for AGE (RAGE) antibody was purchased
sured by sandwich enzyme-linked immunosorbent assay
from Research Diagnostics, Inc. (Flanders, NJ, USA).
(ELISA). Similar experiments were performed to exam-
ine the “priming effect” of normal and uremic plasmaIn vitro plasma perfusion experiments
on cytokine responsiveness.
A 30 mL aliquot of plasma was obtained from a dialysis In separate experiments, we examined the contribu-
patient before the start of five distinct dialysis sessions tion of AGE-modified proteins to cytokine responsive-
and used for in vitro perfusion experiments. In addition, ness. In brief, we preexposed differentiated THP-1 cells
plasma obtained from six healthy volunteers and six dial- to serial dilutions of a neutralizing RAGE monoclonal
ysis patients was used to prime cells during in vitro static antibody. After a 3-hour incubation, cells were washed
experiments. The Human Investigation Review Commit- and primed with uremic plasma for 2 hours followed by
tee approved the study, and all participants gave written LPS, as previously described. Cell supernatants were
informed consent. then assayed for TNF-.
In vitro plasma perfusion was carried out at 37oC. In Finally, we evaluated indirectly whether the column
brief, an in vitro closed-loop perfusion circuit was created also removed AGE-modified proteins by performing simi-
with standard dialysis tubing (Medisystems Corp., Seattle, lar experiments, using plasma obtained after 30 passes
WA, USA) and a column packed with 10 mL of hyper- over the column.
cross-linked copolymer biocompatible beads (BetaSorb,
Measurement of middle moleculesRenalTech International). Before the start of the in vitro
perfusion, the column was rinsed with pyrogen-free iso- 2M was used as a surrogate marker of middle mole-
tonic saline. Plasma was then perfused over the column cules. In brief, plasma 2M levels were measured by a
at a flow rate of 10 mL/min using an AK-10 system pump competitive binding enzyme immunoassay, according to
(Gambro Instrumenta AB, Lund, Sweden) and samples the manufacturer’s instructions. Lower limit of detection
were collected after 10, 20, and 30 passes. All plasma was 0.2 g/mL. The average intra- and interassay coeffi-
cient of variation for 2M was 
10%.samples were frozen at 70oC.
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Statistical analysis
Statistical analyses were performed using the Statisti-
cal Package for Social Sciences version 10.0 (SPSS, Chi-
cago, IL). Kruskal-Wallis ANOVA, Mann Whitney U
test (paired and unpaired), and Friedman test were em-
ployed to test the significance of differences. The Spear-
man rank test was employed to test for correlation be-
tween continuous variables. Results are expressed as
mean  standard error of the mean (SEM). Differences
were considered statistically significant at P 
 0.05.
RESULTS
Effect of the sorbent beads on cytokine responsiveness
We first examined the effect of normal or uremic
plasma on cytokine responsiveness to LPS. Compared
with normal plasma, exposure to uremic plasma resulted
in significantly higher TNF- production (261.1  21.6
vs. 440.5  93.0 pg/mL; P  0.05). By contrast, IL-10
production was nearly significantly lowered after expo-
sure to uremic plasma compared with normal plasma
(131.1  35.2 vs. 85.9  20.1 pg/mL).
We next examined the effect of the sorbent column
on this enhanced proinflammatory cytokine release by
THP-1–derived monocytes. As shown in Figure 1A, com-
pared with baseline, TNF- production markedly de-
creased after 30 passes (629.0  77.7 vs. 144.4  62.2
pg/mL; P  0.043). Similarly, as shown in Figure 1B,
IL-10 production also markedly declined after 30 passes
(206.8 25.1 vs. 116.9 22.9 pg/mL; P 0.043). Overall,
Fig. 1. Effect of the sorbent beads on tumor necrosis factor- (TNF-)TNF- and IL-10 production decreased by 78  9% and
(A ) and interleukin-10 (IL-10) (B ) responsiveness by THP-1–derived47  8%, respectively. monocytes. Differentiated THP-1 cells were primed for 2 hours with
uremic plasma, which was obtained before and after 30 passes over the
Effect of the sorbent beads on plasma removal of 2M perfusion column. Cells were then washed and stimulated with lipopoly-
saccharide (LPS) (10 ng/mL) for 16 hours. TNF- and IL-10 werePredialysis 2M plasma levels were markedly elevated measured in cell supernatants by sandwich enzyme-linked immuno-
at 53.3 1.4 g/mL. However, after 10, 20, and 30 passes sorbent assay (ELISA). Data are mean  SEM of five experiments.
*P  0.04 vs. pass 0.over the 10 mL sorbent column, plasma 2M levels mark-
edly decreased to 4.7  1.0 g/mL, 0.8  0.2 g/mL and
0.2  0.0 g/mL, respectively (P  0.002 by Friedman
exposure to the 1:10 RAGE antibody dilution (553.5 test; Fig. 2). After 20 passes, any further decrease in 2M
135.9 vs. 326.6  70.8 pg/mL; P  0.04).levels did not reach statistical significance. There was a
We finally examined the effect of uremic plasma ob-significant correlation between plasma 2M levels and
tained after 30 passes over the perfusion column on THP-1TNF- production levels (r 0.760; P 0.011 by Spear-
responsiveness after RAGE neutralization. As shown inman rank test).
Figure 4, preexposure of cells to the neutralizing RAGE
antibody (at 1:10 dilution) resulted in a further decreaseEffect of RAGE antibody on TNF- responsiveness
in TNF- production by 46  15% (P  0.068). TheseWe first examined the contribution of AGE-modified
results suggest that despite plasma perfusion, AGE-mod-proteins to the priming of THP-1–derived monocytes by
ified proteins of the middle- and/or large-molecular-uremic plasma. As shown in Figure 3, cells preexposed
weight range were still present in the plasma.to rising concentrations of RAGE antibody and then
primed with uremic plasma had marked reduction in
DISCUSSIONLPS-stimulated TNF- production (P  0.02 by Fried-
man test). Indeed, compared with no antibody, LPS- In the present study, we explored whether the sorbent
beads contained in the BetaSorb hemoperfusion col-stimulated TNF- production markedly decreased after
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Fig. 4. Effect of receptor for advanced glycation end products (RAGE)
antibody on THP-1–derived monocyte priming by perfused uremic
plasma (pass 30). Differentiated THP-1 cells were preincubated with
or without RAGE antibody (1:10 dilution) for 3 hours, then washed
and primed for 2 hours with pass 30 uremic plasma, followed by polysac-
charide (LPS) (10 ng/mL) for an additional 16 hours. Tumor necrosis
factor- (TNF-) was measured in cell supernatants. Data are mean 
Fig. 2. Effect of the sorbent beads on removal of beta2-microglobulin SEM of five experiments. P  0.068 vs. no antibody.
(2M). 2M level was measured in plasma samples at baseline and after
10, 20, and 30 passes over the copolymeric beads contained in the
BetaSorb perfusion column by a competitive binding enzyme immu-
noassay technique. Data are mean  SEM of five experiments. *P 
0.04 vs. pass 0. results also indicate that the column removes 2M effi-
ciently, a surrogate marker of middle molecules.
The enhanced cytokine responsiveness following expo-
sure of monocytes to uremic plasma suggests that uremic
retention solute(s) prime(s) cells to enhanced production
of proinflammatory cytokines. This may contribute to the
chronic microinflammatory state of uremia. The marked
decrease in the bioreactivity of uremic plasma following
perfusion over the sorbent beads incriminates the re-
moval of toxins in the middle-molecular-weight range.
Although the mechanism behind the marked decline in
cytokine production by monocytes after in vitro perfu-
sion is elusive, we attempted to examine this question.
Compared to AGE-modified 2M, native 2M has not
been reported to affect cytokine production by mono-Fig. 3. Effect of receptor for advanced glycation end products (RAGE)
antibody on THP-1–derived monocyte priming by uremic plasma. Dif- cytes [2]. Consequently, we performed additional experi-
ferentiated THP-1 cells were preexposed to RAGE antibody for 3 ments using neutralizing RAGE antibodies, where wehours, then washed and primed with uremic plasma for 2 hours. followed
first observed that AGE receptor blockade markedlyby lipopolysaccharide (LPS) (10 ng/mL) for an additional 16 hours.
Tumor necrosis factor- (TNF-) was measured in cell supernatants. reduces monocyte priming by uremic plasma, suggesting
Data are mean  SEM of five experiments. P  0.02 by Friedman test. a strong involvement of this toxin solute in cytokine*P  0.04 vs. no antibody.
production. Because AGE-2M levels were not measured
in this study, we can only speculate whether the sorbent
beads also removed AGE-2M, resulting in marked re-
duction in cytokine generation by monocytes. These dataumn modulate cytokine responsiveness by THP-1–derived
monocytes. Our results first indicate that compared with are in agreement with recent findings, which demonstrated
that AGE-2M prepared in vitro can enhance cytokinenormal plasma, uremic plasma enhanced LPS-stimulated
TNF- production, which was, in turn, markedly reduced production [12]. Of note, patients with chronic kidney
disease have high concentrations of AGEs in tissue andby the sorbent. Of note, 30-pass TNF- levels were nor-
malized to those observed with nonuremic plasma. LPS- plasma, due to impaired elimination. In addition, new
findings suggest that AGE-2M levels are also elevatedstimulated IL-10 production was not significantly low-
ered after priming with uremic plasma compared with among patients with end-stage renal disease [13, 14].
We attempted to examine indirectly whether the col-normal plasma. However, IL-10 production further de-
creased after in vitro perfusion over the column. Of note, umn also removes AGE-modified proteins. This was
achieved by adding RAGE antibody to plasma samplesthe concomitant reduction in IL-10 production is not
inconsistent with the anti-inflammatory property of this that had been subjected to 30 passes over the column. We
observed that even in this maximally perfused plasmamolecule, which is normally produced in response to
TNF-, and acts to diminish transcription and production sample, THP-1 cell preincubation with RAGE antibody
resulted in a further decline in TNF- production, sug-of TNF- and other proinflammatory cytokines [11]. The
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